Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEdoardo CampodonicoMCMelania CelliAAAndrea Assanelli

Discussion

Loading...

Member takes

Overview

Observational study reveals CAR-T improves outcomes in refractory SCNSL patients, suggesting tailored therapies might be beneficial.

Key Points

  • To examine the efficacy of CAR-T therapy in treating patients with refractory secondary CNS lymphoma (SCNSL) after high-dose methotrexate-based chemotherapy.
  • Evaluated SCNSL patients for CAR-T eligibility between 07/22 and 03/25
  • Provided holding therapies based on prior treatments
  • Eligible patients underwent lymphocytoapheresis before CAR-T infusion
  • 16 of 23 patients achieved remission and were eligible for CAR-T
  • 12 of 16 infused patients remain relapse-free at a median follow-up of 8 months
  • Tocilizumab successfully treated cases of CRS

Cite This Study

Campodonico et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8ebhttps://doi.org/10.1182/blood-2025-7241
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells2024 · 10 citations
  2. 2Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  3. 3Tandem combination of <scp>ASCT</scp> and <scp>CAR</scp> T‐cell therapy in highly refractory <scp>CNS</scp> lymphomas2025
  4. 4Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025
  5. 5Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma2026 · 6 citations